Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology

• Published in: Vaccine Vol. 40; no. 41; pp. 5892 - 5903
• Main Authors: Hemmi, Takuya, Ainai, Akira, Hashiguchi, Takao, Tobiume, Minoru, Kanno, Takayuki, Iwata-Yoshikawa, Naoko, Iida, Shun, Sato, Yuko, Miyamoto, Sho, Ueno, Akira, Sano, Kaori, Saito, Shinji, Shiwa-Sudo, Nozomi, Nagata, Noriyo, Tamura, Koji, Suzuki, Ryosuke, Hasegawa, Hideki, Suzuki, Tadaki
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 29.09.2022; Elsevier Limited
• Subjects: Adaptive immunity; adjuvants; Adjuvants, Immunologic; Administration, Intranasal; Allergy and Immunology; alum; Alum Compounds; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antigens; blood serum; CD4-positive T-lymphocytes; Clinical trials; Combined vaccines; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 infection; COVID-19 Vaccines; Disease control; Experiments; FDA approval; Humans; Immune response; Immune system; Immunoglobulin A; Immunoglobulin A, Secretory; Immunoglobulin G; immunopathology; Infections; Infectious diseases; Influenza; Intranasal vaccination; Leukocytes (eosinophilic); Lung; Lung eosinophilic immunopathology; Lungs; lymph; Lymph nodes; Lymphocytes T; Mice; mRNA vaccines; Mucosa; Mutation; nasal mucosa; oligodeoxyribonucleotides; Oligonucleotides; pandemic; Pandemics; Pneumonia; protective effect; Proteins; Respiratory diseases; Respiratory syncytial virus; Respiratory tract; respiratory tract diseases; Risk; SARS-CoV-2; secretory IgA antibody; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus; Spike protein; Vaccination; Vaccines; Viral diseases; Viral infections; Viruses; γ-Interferon; Japan; COVID-19; SARS-CoV-2; secretory IgA antibody; Intranasal vaccination; Lung eosinophilic immunopathology

To control the coronavirus disease 2019 (COVID-19) pandemic, there is a need to develop vaccines to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. One candidate is a nasal vaccine capable of inducing secretory IgA antibodies in the mucosa of the upper r...